<p>“−“ indicates that the antibody titer is below detection level at 1∶20 serum dilution.</p>*<p>significant difference for CD4bs mAb competition antibodies between patient sera with Narrow or Broad NAb activities (p = 0.0014 by Fisher exact test).</p
<p>(A) ADCC activity of parental ibalizumab and anti-CD4 variant V<sub>H</sub>Y99A alone or in combi...
Interferon (IFN) beta therapy for multiple sclerosis (MS) is associated with the development of bind...
<p>The binding of 12.8 is reduced by over 60% and the binding by 12.10 reduced by 30% suggesting tha...
*<p>The mAb 2G12 competition assays were conducted against SF162 while the PG9 competition assays we...
<p>Titration series of sera from two weeks after the third protein boost were competed with biotinyl...
<p>The ability of serially diluted human immune serum to outcompete binding of mAb to a JR-FL & VSV-...
a<p>Competing MAbs, SFTS patients derived were designated as “H” for the first letter; and mouse der...
<p>The <i>y</i>-axis shows sensitivity to CD4bs mAbs b12 (<b>A</b>) and VRC01 (<b>B</b>) as measured...
<p>Assay was performed with three HIV-1 positive serum samples and respective mAb controls (1F7, 2G1...
<p>A) The presence of co-receptor binding site-directed antibodies was assayed by competition with t...
<p>The presence of CD4bs antibodies in ART-naive HIV-1 infected patients (HIV-1) was evaluated by EL...
<p>Eleven (AIIMS 615, 616, 617, 619, 621, 642, 660, 206, 239, 249) CNP samples were tested for the p...
<p>The MAb CT11F9 (10 µg/g) competed with eight human serum samples for specifically binding to EV71...
<p>Each 1A4 subclass mAb was assessed for its ability to compete with 1A4 IgG1 HRP conjugate for bin...
a<p>FL = full-length native Mab. All data show antibody inhibition of toxin-induced IFNγ release, ...
<p>(A) ADCC activity of parental ibalizumab and anti-CD4 variant V<sub>H</sub>Y99A alone or in combi...
Interferon (IFN) beta therapy for multiple sclerosis (MS) is associated with the development of bind...
<p>The binding of 12.8 is reduced by over 60% and the binding by 12.10 reduced by 30% suggesting tha...
*<p>The mAb 2G12 competition assays were conducted against SF162 while the PG9 competition assays we...
<p>Titration series of sera from two weeks after the third protein boost were competed with biotinyl...
<p>The ability of serially diluted human immune serum to outcompete binding of mAb to a JR-FL & VSV-...
a<p>Competing MAbs, SFTS patients derived were designated as “H” for the first letter; and mouse der...
<p>The <i>y</i>-axis shows sensitivity to CD4bs mAbs b12 (<b>A</b>) and VRC01 (<b>B</b>) as measured...
<p>Assay was performed with three HIV-1 positive serum samples and respective mAb controls (1F7, 2G1...
<p>A) The presence of co-receptor binding site-directed antibodies was assayed by competition with t...
<p>The presence of CD4bs antibodies in ART-naive HIV-1 infected patients (HIV-1) was evaluated by EL...
<p>Eleven (AIIMS 615, 616, 617, 619, 621, 642, 660, 206, 239, 249) CNP samples were tested for the p...
<p>The MAb CT11F9 (10 µg/g) competed with eight human serum samples for specifically binding to EV71...
<p>Each 1A4 subclass mAb was assessed for its ability to compete with 1A4 IgG1 HRP conjugate for bin...
a<p>FL = full-length native Mab. All data show antibody inhibition of toxin-induced IFNγ release, ...
<p>(A) ADCC activity of parental ibalizumab and anti-CD4 variant V<sub>H</sub>Y99A alone or in combi...
Interferon (IFN) beta therapy for multiple sclerosis (MS) is associated with the development of bind...
<p>The binding of 12.8 is reduced by over 60% and the binding by 12.10 reduced by 30% suggesting tha...
DOI
Add to ORKG